Skip to main content
. Author manuscript; available in PMC: 2019 Nov 14.
Published in final edited form as: Nano Lett. 2018 Oct 26;18(11):7092–7103. doi: 10.1021/acs.nanolett.8b03096

Figure 3.

Figure 3.

CPCI/DOX-NP tumor imaging in vivo. (a) In vivo blood pharmacokinetics of CPCI-NP, PCLC/TBAI&ICG-NP and free ICG at a dose of 5 mg kg−1 body weight (Data were mean ± s.d., n = 3 for each group). (b) ICGD fluorescence imaging showing tumor accumulation at different time points after tail vein injection and (c) representative in vivo imaging of nude mice bearing orthotopic OSC-3 oral cancer labeled by GFP (DOX dose: 2.5 mg kg−1; total telodendrimer dose: 50 mg kg−1; ICGD dose: 7 mg kg−1). The red arrow points to the tumor site. (d) Representative ex vivo ICGD fluorescence imaging of the organs and tumor excised at 48 h post-injection time from the same animal. (e) Imaging of the distribution of CPCI/DOX-NP in OSC-3 tumor tissue at 48 h after injection (Red: DOX, Green: ICGD, scale bar = 25 μm). (f) Quantitative analysis of ICGD fluorescence signal intensity inside organs and tumor at 48 h post injection of CPCI/DOX-NP. (g) DOX distribution in organs and tumors tissues of orthotopic OSC-3 oral cancer mice 24 h, 48 h and 5 d post injection of CPCI/DOX-NP. Dose of DOX: 2.5 mg kg−1; data were mean±s.d., n = 3 for each time point.